Patents Assigned to INOVIO PHARMACEUTICALS, INC.
-
Patent number: 11007265Abstract: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.Type: GrantFiled: November 6, 2018Date of Patent: May 18, 2021Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David B. Weiner, Matthew P. Morrow
-
Patent number: 10933130Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.Type: GrantFiled: August 30, 2018Date of Patent: March 2, 2021Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
-
Patent number: 10925961Abstract: Disclosed herein is a vaccine comprising an antigen and CD40L. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.Type: GrantFiled: March 18, 2016Date of Patent: February 23, 2021Assignees: The Trustees of the University of Pennsylvania, INOVIO PHARMACEUTICALS. INC.Inventors: David Weiner, Matthew Morrow, Megan Wise
-
Patent number: 10905870Abstract: The present invention relates to electroporation (EP) devices that are able to generate an electroporation causing electrical field at the mucosal layer, and preferably in a tolerable manner. Further, it includes the generation of a protective immune response, cellular and/or humoral, using the oral EP device along with a genetic construct that encodes an immunogenic sequence.Type: GrantFiled: November 12, 2018Date of Patent: February 2, 2021Assignee: Inovio Pharmaceuticals, Inc.Inventors: Stephen V. Kemmerrer, Kate Broderick, Jay McCoy
-
Patent number: 10905755Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.Type: GrantFiled: March 11, 2019Date of Patent: February 2, 2021Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Jian Yan
-
Patent number: 10835595Abstract: Disclosed herein is a vaccine comprising an antigen and PD1 antibody and/or PDL1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.Type: GrantFiled: January 6, 2015Date of Patent: November 17, 2020Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Karuppiah Muthumani, Niranjan Sardesai
-
Patent number: 10668279Abstract: The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.Type: GrantFiled: February 1, 2018Date of Patent: June 2, 2020Assignee: Inovio Pharmaceuticals, Inc.Inventors: Kate Broderick, Jay McCoy, Stephen V. Kemmerrer
-
Patent number: 10548971Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.Type: GrantFiled: June 29, 2018Date of Patent: February 4, 2020Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Publication number: 20190284263Abstract: Disclosed herein are methods of delivering an agent to a subject. Further disclosed herein are methods of treating a disease or disorder in a subject. The methods may include administering to the subject a chondroitinase polypeptide or a polynucleotide encoding a chondroitinase polypeptide in an amount sufficient to degrade glycosaminoglycans, and administering to the subject the agent. The methods may further include administering a hyaluronidase polypeptide or a polynucleotide encoding a hyaluronidase.Type: ApplicationFiled: May 1, 2017Publication date: September 19, 2019Applicant: Inovio Pharmaceuticals, Inc.Inventors: Trevor Smith, Nina SCHOMMER, Kate BRODERICK, Bryan YUNG, Katherine SCHULTHEIS
-
Patent number: 10398769Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA Influenza A of serotype H7N9 alone and in combination with HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided.Type: GrantFiled: August 4, 2014Date of Patent: September 3, 2019Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David B. Weiner, Jian Yan
-
Patent number: 10232030Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV6 E6E7, HPV11 E6E7, HPV16 E6E7, HPV18 E6E7, HPV31 E6E7, HPV33 E6E7, HPV39 E6E7, HPV45 E6E7, HPV52 E6E7, and HPV58 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.Type: GrantFiled: March 12, 2014Date of Patent: March 19, 2019Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David B. Weiner, Jian Yan
-
Patent number: 10226526Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.Type: GrantFiled: November 21, 2016Date of Patent: March 12, 2019Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David Weiner, Jian Yan
-
Patent number: 10220082Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.Type: GrantFiled: December 13, 2013Date of Patent: March 5, 2019Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David B. Weiner, Jian Yan, Jewell Walters
-
Patent number: 10166288Abstract: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.Type: GrantFiled: September 29, 2015Date of Patent: January 1, 2019Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David B. Weiner, Matthew P. Morrow
-
Patent number: 10130705Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.Type: GrantFiled: October 2, 2014Date of Patent: November 20, 2018Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
-
Patent number: 10124159Abstract: The present invention relates to electroporation (EP) devices that are able to generate an electroporation causing electrical field at the mucosal layer, and preferably in a tolerable manner. Further, it includes the generation of a protective immune response, cellular and/or humoral, using the oral EP device along with a genetic construct that encodes an immunogenic sequence.Type: GrantFiled: April 28, 2011Date of Patent: November 13, 2018Assignee: Inovio Pharmaceuticals, Inc.Inventors: Stephen V Kemmerrer, Kate Broderick, Jay McCoy
-
Patent number: 10087240Abstract: The present invention relates to a composition including a recombinant nucleic acid sequence that encodes an antibody and a method of generating a synthetic antibody in a subject by administering the composition to the subject. The invention also provides a method of preventing and/or treating disease in a subject using the composition and method of generation.Type: GrantFiled: December 13, 2014Date of Patent: October 2, 2018Assignee: INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
-
Patent number: 10016497Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.Type: GrantFiled: November 26, 2014Date of Patent: July 10, 2018Assignees: THE TRUSTEES OF THE UNIVERSTIY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Patent number: 9993545Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.Type: GrantFiled: March 17, 2014Date of Patent: June 12, 2018Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David B. Weiner, Jian Yan, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Patent number: 9987347Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes.Type: GrantFiled: March 14, 2014Date of Patent: June 5, 2018Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.Inventors: David B. Weiner, Jian Yan, Niranjan Sardesai